Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ras-Related Protein Rab-32 and Thrombospondin 1 Confer Resistance to the EGFR Tyrosine Kinase Inhibitor Osimertinib by Activating Focal Adhesion Kinase in Non-Small Cell Lung Cancer.
Kosibaty Z, Brustugun OT, Zwicky Eide IJ, Tsakonas G, Grundberg O, De Petris L, McGowan M, Hydbring P, Ekman S. Kosibaty Z, et al. Among authors: brustugun ot. Cancers (Basel). 2022 Jul 14;14(14):3430. doi: 10.3390/cancers14143430. Cancers (Basel). 2022. PMID: 35884490 Free PMC article.
PIK3CA mutations as prognostic factor in squamous cell lung carcinoma.
McGowan M, Hoven AS, Lund-Iversen M, Solberg S, Helland Å, Hirsch FR, Brustugun OT. McGowan M, et al. Among authors: brustugun ot. Lung Cancer. 2017 Jan;103:52-57. doi: 10.1016/j.lungcan.2016.11.018. Epub 2016 Nov 28. Lung Cancer. 2017. PMID: 28024696
High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial.
Grønberg BH, Killingberg KT, Fløtten Ø, Brustugun OT, Hornslien K, Madebo T, Langer SW, Schytte T, Nyman J, Risum S, Tsakonas G, Engleson J, Halvorsen TO. Grønberg BH, et al. Among authors: brustugun ot. Lancet Oncol. 2021 Mar;22(3):321-331. doi: 10.1016/S1470-2045(20)30742-7. Lancet Oncol. 2021. PMID: 33662285 Clinical Trial.
Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study.
Eide IJZ, Grut H, Helland Å, Ekman S, Sørensen JB, Hansen KH, Grønberg BH, Cicenas S, Koivunen JP, Mellemgaard A, Brustugun OT. Eide IJZ, et al. Among authors: brustugun ot. Acta Oncol. 2021 Dec;60(12):1565-1571. doi: 10.1080/0284186X.2021.1973092. Epub 2021 Sep 6. Acta Oncol. 2021. PMID: 34486915 Clinical Trial.
Epidemiology and Survival Outcomes for Patients With NSCLC in Scandinavia in the Preimmunotherapy Era: A SCAN-LEAF Retrospective Analysis From the I-O Optimise Initiative.
Ekman S, Horvat P, Rosenlund M, Kejs AM, Patel D, Juarez-Garcia A, Lacoin L, Daumont MJ, Penrod JR, Brustugun OT, Sørensen JB. Ekman S, et al. Among authors: brustugun ot. JTO Clin Res Rep. 2021 Mar 24;2(5):100165. doi: 10.1016/j.jtocrr.2021.100165. eCollection 2021 May. JTO Clin Res Rep. 2021. PMID: 34590017 Free PMC article.
147 results